CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07909031
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Gastric/GEJ
- Biliary Tract Cancer (BTC)
- Esophageal Squamous Cell Carcinoma (ESCC)
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer Metastatic
- Non-small Cell Lung Cancer (NSCLC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Crescent Biopharma, Inc.
- Last updated on ClinicalTrials.gov
- November 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 2
- Clinical Study Site · Austin, TX
- Clinical Study Site · Dallas, TX
Virginia · 1
- Clinical Study Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.